BRPI0409742A - uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica - Google Patents
uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêuticaInfo
- Publication number
- BRPI0409742A BRPI0409742A BRPI0409742-4A BRPI0409742A BRPI0409742A BR PI0409742 A BRPI0409742 A BR PI0409742A BR PI0409742 A BRPI0409742 A BR PI0409742A BR PI0409742 A BRPI0409742 A BR PI0409742A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- tyrosine kinases
- angiogenic agent
- src family
- pharmaceutical composition
- Prior art date
Links
- 239000004037 angiogenesis inhibitor Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000013066 combination product Substances 0.000 title abstract 2
- 229940127555 combination product Drugs 0.000 title abstract 2
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 title abstract 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102000001332 SRC Human genes 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 102000009076 src-Family Kinases Human genes 0.000 abstract 1
- 108010087686 src-Family Kinases Proteins 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"USO DE UM AGENTE ANTI-ANGIOGêNICO, EM COMBINAçãO COM UM INIBIDOR DA FAMìLIA SRC DE TIROSINA QUINASES NãO-RECEPTORAS, PRODUTO DE COMBINAçãO, E, COMPOSIçãO FARMACêUTICA". A invenção refere-se ao uso de um agente anti-angiogênico, em combinação com um inibidor da família Src das tirosina quinases não-receptoras, na fabricação de um medicamento para uso no tratamento substancialmente normotenso de um mamífero de sangue quente, tal como um ser humano, de um estado doentio associado com a angiogênese, o inibidor da Src quinase sendo administrado em uma quantidade eficaz, para neutralizar substancialmente a hipertensão induzida pelo agente anti-angiogênico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0310401.5A GB0310401D0 (en) | 2003-05-07 | 2003-05-07 | Therapeutic agent |
| PCT/GB2004/001939 WO2004098604A1 (en) | 2003-05-07 | 2004-05-04 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0409742A true BRPI0409742A (pt) | 2006-05-09 |
Family
ID=9957542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0409742-4A BRPI0409742A (pt) | 2003-05-07 | 2004-05-04 | uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20060223815A1 (pt) |
| EP (1) | EP1620104A1 (pt) |
| JP (1) | JP2006525304A (pt) |
| KR (1) | KR20060009893A (pt) |
| CN (1) | CN100418531C (pt) |
| AU (1) | AU2004237132B2 (pt) |
| BR (1) | BRPI0409742A (pt) |
| CA (1) | CA2519930A1 (pt) |
| GB (1) | GB0310401D0 (pt) |
| MX (1) | MXPA05011858A (pt) |
| NO (1) | NO20054411L (pt) |
| NZ (1) | NZ542348A (pt) |
| WO (1) | WO2004098604A1 (pt) |
| ZA (1) | ZA200508858B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US7462623B2 (en) * | 2002-11-04 | 2008-12-09 | Astrazeneca Ab | Quinazoline derivatives as Src tyrosine kinase inhibitors |
| GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| CA2553433A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer |
| JP4932495B2 (ja) | 2004-01-23 | 2012-05-16 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
| GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| US20080113039A1 (en) * | 2004-03-23 | 2008-05-15 | Stephen Robert Wedge | Combination Therapy |
| GB0412074D0 (en) | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
| US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
| GB0427697D0 (en) * | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| WO2007003933A2 (en) * | 2005-07-06 | 2007-01-11 | Astrazeneca Ab | Combination therapy of cancer with azd2171 and gemcitabine |
| CA2620436A1 (en) * | 2005-08-26 | 2007-03-01 | Antisoma Plc | Combinations comprising dmxaa for the treatment of cancer |
| CA2631676A1 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of azd2171 and pemetrexed |
| EP2220078B1 (en) * | 2007-10-29 | 2013-05-22 | Amgen, Inc | Benzomorpholine derivatives and methods of use |
| WO2009068906A2 (en) * | 2007-11-26 | 2009-06-04 | Astrazeneca Ab | Combinations comprising zd4054 and a src family kinase inhibitor 172 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| CA2928665A1 (en) * | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| BRPI0017548B8 (pt) * | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| US7115615B2 (en) * | 2000-08-21 | 2006-10-03 | Astrazeneca | Quinazoline derivatives |
| WO2002092579A1 (en) * | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| US20050222183A1 (en) * | 2002-08-09 | 2005-10-06 | Wedge Stephen R | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| DK1592423T3 (da) * | 2003-02-13 | 2011-06-27 | Astrazeneca Ab | Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11 |
| GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| US20060167027A1 (en) * | 2003-07-10 | 2006-07-27 | Wedge Stephen R | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| US20080113039A1 (en) * | 2004-03-23 | 2008-05-15 | Stephen Robert Wedge | Combination Therapy |
| GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0412074D0 (en) * | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
| KR20070073813A (ko) * | 2004-09-27 | 2007-07-10 | 아스트라제네카 아베 | Ａｚｄ2171 및 이마티닙을 포함하는 암의 병합 요법 |
| MX2007003505A (es) * | 2004-09-27 | 2007-05-10 | Astrazeneca Ab | Combinacion que comprende zd6474 e imatinib. |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| JP4834985B2 (ja) * | 2004-12-10 | 2011-12-14 | 日産自動車株式会社 | 組電池の容量調整装置 |
-
2003
- 2003-05-07 GB GBGB0310401.5A patent/GB0310401D0/en not_active Ceased
-
2004
- 2004-05-04 JP JP2006506222A patent/JP2006525304A/ja active Pending
- 2004-05-04 CA CA002519930A patent/CA2519930A1/en not_active Abandoned
- 2004-05-04 WO PCT/GB2004/001939 patent/WO2004098604A1/en not_active Ceased
- 2004-05-04 AU AU2004237132A patent/AU2004237132B2/en not_active Ceased
- 2004-05-04 EP EP04731049A patent/EP1620104A1/en not_active Withdrawn
- 2004-05-04 MX MXPA05011858A patent/MXPA05011858A/es unknown
- 2004-05-04 US US10/555,389 patent/US20060223815A1/en not_active Abandoned
- 2004-05-04 NZ NZ542348A patent/NZ542348A/en unknown
- 2004-05-04 KR KR1020057020997A patent/KR20060009893A/ko not_active Ceased
- 2004-05-04 BR BRPI0409742-4A patent/BRPI0409742A/pt not_active IP Right Cessation
- 2004-05-04 CN CNB2004800120898A patent/CN100418531C/zh not_active Expired - Fee Related
-
2005
- 2005-09-23 NO NO20054411A patent/NO20054411L/no not_active Application Discontinuation
- 2005-11-01 ZA ZA200508858A patent/ZA200508858B/en unknown
-
2009
- 2009-09-28 US US12/568,643 patent/US20100029673A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1784232A (zh) | 2006-06-07 |
| US20060223815A1 (en) | 2006-10-05 |
| CA2519930A1 (en) | 2004-11-18 |
| GB0310401D0 (en) | 2003-06-11 |
| CN100418531C (zh) | 2008-09-17 |
| NO20054411L (no) | 2005-11-30 |
| WO2004098604A1 (en) | 2004-11-18 |
| AU2004237132A1 (en) | 2004-11-18 |
| MXPA05011858A (es) | 2006-02-17 |
| AU2004237132B2 (en) | 2007-10-18 |
| NO20054411D0 (no) | 2005-09-23 |
| KR20060009893A (ko) | 2006-02-01 |
| JP2006525304A (ja) | 2006-11-09 |
| ZA200508858B (en) | 2007-03-28 |
| NZ542348A (en) | 2009-01-31 |
| US20100029673A1 (en) | 2010-02-04 |
| EP1620104A1 (en) | 2006-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28213A1 (es) | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. | |
| BR0316170A (pt) | Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer | |
| HN2005000255A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
| DOP2009000135A (es) | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituídos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
| BR0109729A (pt) | Uso de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo, kit para uso na produção de um efeito anti-angiogênico e/ou efeito redutor da permeabilidade vascular em um animal de sangue quente, e, método de tratamento de um estado doentio associado com a angiogênese | |
| CU23821A3 (es) | Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer | |
| PA8479201A1 (es) | Derivados del acido hidroxi-pipecolato hidroxamico | |
| BRPI0410260A (pt) | composição conjugada para medicamento | |
| CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
| BRPI0414876A (pt) | compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos | |
| MXPA05011858A (es) | Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico. | |
| EA200802118A1 (ru) | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях | |
| SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
| BRPI0806863B8 (pt) | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv | |
| BRPI0417833A (pt) | novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6 | |
| PE20212158A1 (es) | Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso | |
| BRPI0406796A (pt) | Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina | |
| BRPI0409818A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BR0206819A (pt) | Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca | |
| BRPI0411429A (pt) | tratamento de sintomas associados com vaginose bacteriana | |
| DE60019947D1 (de) | Vorbeugung von kolorektalkrebs | |
| BR0213696A (pt) | Agonistas do receptor de acetilcolina nicotìnicos no tratamento da sìndrome de pernas inquietas | |
| SE0000303D0 (sv) | Novel compounds | |
| BRPI0517983A (pt) | uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |